Promoter holding
64.27%
AF
Acme Formulation - Due diligence report
A 360° intelligence report on Acme Formulation: trust score, financial health, credit view, compliance, directors, growth and distress signa…
Full Due-Diligence Report + Documents
- Unlock all financial figures & 5-year trends
- Full trust, health & credit-risk scores
- Director details, charges & MCA documents
₹700
₹449
Save ₹251
excl. GST
Or from ₹279/report with credits
View credit packages
Company Credits – Starter
- One credit unlocks this full due-diligence report
- Use across any company’s report, anytime
- Credits valid for 12 months
Choose your own credit amount
View credit packages
Acme Formulation — 360° Intelligence Report
Generated from MCA filings & public records73/100
Trust Score
Moderate
Acme Formulation is assessed as Moderate with a Trust Score of 73/100. Acme Formulation is an active private limited indian non-government company incorporated in 2004, operating in the Pharma sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a moderate compliance risk and moderate financial risk profile.
Report generated on 29 Sep 2026 from the latest processed filings. Acme Formulation Private Limited snapshot & full profile →
Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.
02
Score Card
Higher is safer · rule-based & explainableTrust ScoreModerate
73/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreModerate
56/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreModerate
70/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreModerate
70/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
85/100
Revenue, profit, asset and hiring momentum.
Distress ScoreModerate
65/100
Early-warning signals - higher means fewer warnings.
03
Financial Intelligence Dashboard
Consolidated · 5 filed year(s)Unlock the full 5-year financial dashboard with charts and year-wise figures.
Get full accessScores and observations on this page are already computed from the real filings - only the underlying figures are locked.
04
Credit & Compliance Intelligence
Why the scores are what they are
Credit Risk Score: 70/100 Moderate
- Profitable - internal accruals available.
- Externally credit-rated (B+).
Charges position: 4 open (115.72 cr) · 14 satisfied (202.58 cr).
Banking relationships (from registered charges)
| Lender | Charges | Amount |
|---|---|---|
| State Bank Of India | 3 | 48.0 cr |
| Hdfc Bank Limited | 4 | 48.0 cr |
| Standard Chartered Bank | 3 | 48.0 cr |
| Aditya Birla Finance Limited | 1 | 48.0 cr |
| Small Industries Development Bank Of India | 3 | 48.0 cr |
| Standard Chartered Bank (Acting As An Security Agent Of Scb Mauritius) | 1 | 48.0 cr |
Compliance Score: 56/100 Moderate
- Company status is Active as per MCA.
- Balance sheet slightly behind (Mar 2024).
- Litigation present in 2 court forum(s).
- 1 auditor resignation(s) filed - latest: AJAY JAIN AND CO. on 2021-11-30.
- Delayed payments to MSME suppliers disclosed (289 disclosure(s)).
- 3 active GST registration(s).
Legal cases on record (2)
05
Director Intelligence
Stability score: 95/100| Name | DIN / PAN | Designation | Appointed | Tenure | DIN status |
|---|---|---|---|---|---|
| VIKAS SHARMA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| ASWIN VIKRAM | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| GINNY UPPAL | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| NIKHILKUMAR SRIVASTAVA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| VIRAL SHAH | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| VIRAL SHAH | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
- 6 directors on the board.
- No disqualified or deactivated DINs.
- Stable board - no exits in 3 years.
- Average tenure above 5 years.
Director & KMP remuneration (FY 2023)
| Name | Designation | Total remuneration |
|---|---|---|
| A K Sharma | Managing Director | 2.4 cr |
| R Mehta | Whole-time Director | 1.6 cr |
| S Iyer | CFO | 95.0 L |
Remuneration is disclosed in the latest annual return. Unlock full report
06
Ownership & Group Intelligence
As per FY 2025 annual returnPublic / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
Pagac Ariane Pte Ltd
Subsidiaries
4
Group entities
4
Capital events
2 allotment(s) · 0 transfer(s)
Promoters hold a majority stake - exact percentages are part of the full report.
| Group entity | Relationship | % held |
|---|---|---|
| Ace Invest Private Limited | Subsidiary Company | 74.00% |
| Ace Testing Solutions Private Limited | Subsidiary Company | 74.00% |
| Acme Generics Private Limited | Subsidiary Company | 74.00% |
| Immacule Lifesciences Private Limited | Subsidiary Company | 74.00% |
| Pagac Ariane Pte Ltd | Holding Company | 74.00% |
Key managerial personnel: VIKAS SHARMA (Whole-time director) · VIRAL SHAH (Managing Director) · VIRAL SHAH (CEO)
Full shareholding pattern, group structure & capital events →
07
Risk Intelligence Center
Growth 85 · Distress 65
Growth signals & trust indicators
Steady revenue growth: +38% over 4 year(s).
Profit expanded 1.42 year-on-year.
Asset base grew 2.1x - capacity expansion.
Net margin improved to 24%.
EPFO headcount growing - hiring signal.
Operating for 22+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Revenue declined year-on-year.
Outside liabilities up 0.86 in a year.
Compliance score is weak (56/100).
4 open charge(s) registered - assets are encumbered.
1 auditor resignation(s) on record - review the stated reasons.
MSME payment delays disclosed - latest outstanding 5.04 cr.
2 court case(s) on record - see the legal section for details.
08
Stakeholder Verdicts
Vendor · Banker · InvestorVendor due diligence64/100
Review suggested
Suitability as a supplier / customer counterparty.
- Check the compliance flags before onboarding.
- 2 distress signal(s) - see Risk Center.
- Financial filings available for verification.
Banker assessment66/100
Mixed indicators - deeper appraisal suggested
Indicative lending comfort for banks, NBFCs and trade credit.
- Debt capacity assessed from filed statements.
- 4 open charge(s) of 115.72 cr already registered.
- Compliance gaps should be priced into terms.
Investor view77/100
Positive growth indicators
Growth quality and scalability through an investor lens.
- 5 growth signal(s) detected.
- Margin and return trends computable from filings.
- Management team looks stable.
09
MCA Filings & Events Timeline
Latest 15 events15 Oct 2024
Director appointed
GINNY UPPAL (Company Secretary)
30 Sep 2024
Last AGM held
Annual general meeting
31 Mar 2024
Latest balance sheet
Filed with ROC
01 Apr 2023
Director ceased
ANNASWAMY VAIDHEESH
22 Nov 2022
Director ceased
SUNDAR RAJ ANANTHAKRISHNAN
26 Aug 2022
Charge satisfied
General Manager District Industries Centre
17 Jun 2022
Director ceased
LINCOLN LIN FENG PAN
26 May 2022
Charge satisfied
State Bank Of India
20 Oct 2021
Director ceased
RAM GOPAL ARORA
04 Oct 2021
Director appointed
ASWIN VIKRAM (Director)
Director appointed
NIKHILKUMAR SRIVASTAVA (Director)
30 Sep 2021
Securities allotted
2614610 Preference Shares - 547.74 cr raised
10 Sep 2021
Charge satisfied
Hdfc Bank Limited
06 Aug 2021
Charge created
State Bank Of India - 50.72 cr
22 Jan 2021
Securities allotted
676088 Equity Shares - 67.61 Lakh raised
10
Key Observations
Auto-generated from the data aboveRevenue grew 61% over the last 4 financial year(s).
Net profit margin moved from 38% to 1.42.
Debt-to-equity stands at 2.1x - leverage worth monitoring.
Net worth is positive.
6 active director(s) / partner(s); board looks stable and experienced.
3 active GST registration(s) indicate ongoing business operations.
Operates a group structure with 4 subsidiary(ies) - assess on a consolidated basis.
Carries an external credit rating of B+ from Icra.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a majority stake as per the FY 2025 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 2 security allotment(s) - amounts available in the full report.
| Company | CIN | Location |
|---|---|---|
| Niine Private Limited | U24100UP2021PTC150579 | Gorakhpur, Uttar Pradesh, India |
| Naprod Life Sciences Private Limited | U24230MH1990PTC057496 | Mumbai, Maharashtra, India |
| Crop Chemicals India Limited | U24219PB2003PLC026162 | Punjab, Punjab, India |
| The Tata Pigments Limited | U24100JH1983PLC001836 | Jamshedpur, Jharkhand, India |
| Chemcon | L24231GJ1988PLC011652 | Baroda, Gujarat, India |
| Charak Pharma | U24230MH2000PTC127072 | Mumbai, Maharashtra, India |
| Aadi Polymers Private Limited | U24100DL2009PTC190126 | Delhi, Delhi, India |
| Nestorpharma | U24231DL1975PLC007959 | New Delhi, Delhi, India |
12
Who Uses This Report
CA · CS · Banker · Investor · VendorChartered Accountants (CA)
Verify Acme Formulation before audits and certifications: compliance score 56/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.
Company Secretaries (CS)
Track statutory health of Acme Formulation: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.
Bankers & NBFCs
Current banker verdict: Mixed indicators - deeper appraisal suggested. Credit risk score 70/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.
Investors & Analysts
Investor view: Positive growth indicators. Growth score 85/100, margin trends, ownership structure and peer set for Acme Formulation - screening before a deeper diligence.
Vendors & Procurement Teams
Vendor verdict: Review suggested. Trust score 73/100, distress signals and MSME payment-delay disclosures - know whether Acme Formulation pays its suppliers before you extend credit terms.
Lawyers & Compliance Teams
Litigation footprint (2 case(s) on record), regulatory flags, charge documents trail and director networks for Acme Formulation - groundwork for KYC, onboarding and disputes.
13
Frequently Asked Questions
Is Acme Formulation an active company?
Acme Formulation has MCA status “Active” with a compliance score of 56/100 (Moderate).
Is Acme Formulation financially healthy?
Acme Formulation has a Financial Health Score of 70/100 (Moderate) based on its filed financial statements.
Should I do business with Acme Formulation?
Its overall Trust Score is 73/100 (Moderate). Vendor verdict: Review suggested. Review the risk flags in the Risk Intelligence Center before deciding.
Who controls Acme Formulation?
The ultimate holding entity is Pagac Ariane Pte Ltd. 6 active director(s) are on record.
Does Acme Formulation have loans or charges against its assets?
4 open charge(s) are registered against its assets, and 14 earlier charge(s) stand satisfied.
Is Acme Formulation up to date with its ROC filings?
Balance sheet slightly behind (Mar 2024). Overall compliance score: 56/100 (Moderate).
Is it risky to lend to Acme Formulation?
Its Credit Risk Score is 70/100 (Moderate). Banker verdict: Mixed indicators - deeper appraisal suggested.
Disclaimer: This report is generated automatically from MCA filings and public records as available
in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the
underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are
not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice.
Verify from official sources and consult a qualified professional before any business, lending or investment decision.
If you represent this company and believe any information is inaccurate or outdated,
report it here and we will review promptly.
